Cue Biopharma, Inc. (CUE) AI Stock Analysis

Cue Biopharma, Inc. is an innovative clinical-stage biopharmaceutical firm dedicated to advancing biologic drugs tailored for precise modulation of the human immune system. The company focuses on treating cancers, chronic infectious diseases, and autoimmune disorders. Its lead candidate, CUE-101, is a fusion protein biologic in Phase 1b clinical trials designed to activate antigen-specific T cells against human papilloma virus-driven cancers. Its pipeline also includes CUE-102, CUE-103 targeting the KRAS G12V mutation, CUE-200 addressing T cell exhaustion, and the CUE-300 and CUE-400 frameworks. The company collaborates with Merck Sharp & Dohme Corp., LG Chem Life Sciences, and Albert Einstein College of Medicine.

Cue Biopharma has experienced significant top-line volatility. Annual revenue shifted from $14.9M in FY2021 to $1.2M in FY2022, before rising to $5.5M in FY2023, $9.3M in FY2024, and $27.5M in FY2025, representing a 5-year revenue CAGR of 54.2%. Operating margin improved from -4275.1% in FY2022 to -96.6% in FY2025. Net income remained negative across all periods, recording -$44.2M in FY2021, -$53.0M in FY2022, -$50.7M in FY2023, -$40.7M in FY2024, and -$26.6M in FY2025. For the trailing twelve months ended June 30, 2026, revenue stood at $37.7M with quarterly revenue growth of 166.7% year-over-year, though operating margin was -1113.3% and EPS was -$29.59.

As of June 30, 2026, Cue Biopharma held $17.4M in cash and short-term investments against total debt of $8.8M, yielding net cash of $8.6M. Shareholders' equity was $2.3M, and total assets were $30.7M. The company reported a current ratio of 1.25 and a debt-to-equity ratio of 3.81. Free cash flow was -$21.9M in FY2025 alongside capital expenditures of $177,000, while the 5-year share count change increased by 503.6%.

Cue Biopharma trades at a price-to-sales multiple of 3.2x, below the 4.1x median of its US-listed Healthcare peers. Its enterprise value stands at $214.9M with an EV-to-revenue multiple of 5.7x. The company's price-to-book ratio is 99.2x. Over the past year, CUE shares declined 29.5%, trailing the S&P 500 return of 16.8%. Over a 5-year span, the stock fell 95.6% compared to an 83.0% gain for the benchmark.

Wall Street coverage consists of 3 Strong Buy ratings, with zero Buy, Hold, Sell, or Strong Sell recommendations. The mean price target is $88.00, representing a 426.6% premium over the last close of $16.71. For the current fiscal year ending December 31, 2026, analysts estimate revenue of $15.6M and EPS of -$25.01. Cue Biopharma beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 11, 2026.

This page is an AI-written research summary of Cue Biopharma, Inc. (CUE). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CUE income statement, CUE balance sheet, CUE key metrics, CUE analyst forecast, CUE chart. See the CUE stock overview for the latest quote and news.